Free Trial
NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Price, News & Analysis

Biora Therapeutics logo
$1.63 +0.01 (+0.62%)
(As of 11/21/2024 ET)

About Biora Therapeutics Stock (NASDAQ:BIOR)

Key Stats

Today's Range
$1.55
$1.67
50-Day Range
$1.62
$6.68
52-Week Range
$1.43
$19.90
Volume
52,333 shs
Average Volume
42,794 shs
Market Capitalization
$7.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biora Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

BIOR MarketRank™: 

Biora Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biora Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Biora Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Biora Therapeutics are expected to grow in the coming year, from ($12.66) to ($7.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    4.76% of the float of Biora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Biora Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Biora Therapeutics has recently increased by 43.32%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Biora Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Biora Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.76% of the float of Biora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Biora Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Biora Therapeutics has recently increased by 43.32%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Biora Therapeutics has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.08% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biora Therapeutics' insider trading history.
Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BIOR Stock News Headlines

Biora Therapeutics (NASDAQ:BIOR) Price Target Raised to $23.00
Biora Therapeutics Faces Nasdaq Delisting Challenges
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Biora Therapeutics Reports Q3 2024 Results and Updates
See More Headlines

BIOR Stock Analysis - Frequently Asked Questions

Biora Therapeutics' stock was trading at $13.50 on January 1st, 2024. Since then, BIOR shares have decreased by 87.9% and is now trading at $1.63.
View the best growth stocks for 2024 here
.

Biora Therapeutics, Inc. (NASDAQ:BIOR) issued its earnings results on Wednesday, November, 10th. The company reported ($4.60) earnings per share for the quarter, beating analysts' consensus estimates of ($4.70) by $0.10. The firm earned $0.18 million during the quarter, compared to analysts' expectations of $11.10 million.

Biora Therapeutics's stock reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biora Therapeutics investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Bank of America (BAC) and Ford Motor (F).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BIOR
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$23.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+1,311.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-124,110,000.00
Pretax Margin
-4,005.83%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($23.58) per share

Miscellaneous

Free Float
2,213,000
Market Cap
$7.37 million
Optionable
Optionable
Beta
1.27
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:BIOR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners